


RECEIVED

FEB 15 2002

TECH CENTER 1600/2301



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.

BY: Rose A. Stowe DATE: January 29, 2002
Rose A. Stowe

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of	: Group Art Unit: 1617
	Bernd Fabry	:
		:
Appln. No.:	09/554,387	: Examiner: Shaojia A.
		: Jiang, Ph.D.
Filed:	June 29, 2000	:
		:
For:	HYPOCHOLESTEREMIC PREPARATIONS	: Attorney Docket
	CONTAINING MIXTURES OF PHYTO-	: No.: H 3185 PCT/US
	STENOL(ESTER)S AND CONJUGATED FATTY:	:
	ACIDS, AND METHODS OF REDUCING	:
	SERUM CHOLESTEROL LEVELS USING THE	:
	SAME	:

REQUEST FOR RECONSIDERATION

This is in response to the Office Action dated August 29, 2001 (Paper No. 12), in the above-identified application. This response is being timely filed as a Petition for a two-month extension of time, up to and including January 29, 2002, including an authorization to charge fees, is being submitted herewith.

Applicant respectfully requests reconsideration of all pending claims and withdrawal of the remaining rejection, in light of the following remarks.

REMARKS

Claims 11-30 are currently pending in the present application.

In Paper No. 12, the Examiner specifically acknowledges withdrawal of the two rejections under 35 U.S.C. §102(b), based upon U.S. Pat. No. 3,865,939 of Jandacek ("Jandacek") and Chemical Abstract No. 100:208354 of Hasegawa, synonymously identified and cited as "XP-002099834", (hereinafter referred to as "Hasegawa").

However, in Paper No. 12, the Examiner rejects claims 11- 30 under 35 U.S.C. §103(a), as being unpatentable over Jandacek and Hasegawa, in view of European Patent